1 / 10

Parkinson's Disease

Parkinson's Disease. James Parkinson-first clinical description of the syndrome. Scott Boline BrainU202-2012. Notables with Parkinson Disease. Adolf Hitler Muhammed Ali Micheal J. Fox-1961-same age as I am James Doohan-Scottie Jim Bakkus-Thurstan Howell III Bob Hoskins Vincent Price

genevieve-harris
Télécharger la présentation

Parkinson's Disease

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Parkinson's Disease James Parkinson-first clinical description of the syndrome Scott Boline BrainU202-2012

  2. Notables with Parkinson Disease Adolf Hitler Muhammed Ali Micheal J. Fox-1961-same age as I am James Doohan-Scottie Jim Bakkus-Thurstan Howell III Bob Hoskins Vincent Price Pope John Paul II Janet Reno Harriet-My Mother-in-law I am sure there is someone you know and love who Has or may have this disease.

  3. Characteristics of Neurological Disorder Parkinson's disease is a progressive disorder of the nervous system that affects your movement. It develops gradually, sometimes starting with a barely noticeable tremor in just one hand. But while tremor may be the most well-known sign of Parkinson's disease, the disorder also commonly causes stiffness or slowing of movement. (Mayo Clinic)

  4. Brain Disease when symptoms evolve over 20 yrs. 5-10 % occur before age of 50 Symptoms Early: Tremor- Diskinesia-not indicator of disease Stiffness, slowness, difficulty walking- Bradykinesia Small, Crowded handwriting Stooped Posture “Masked” face frozen in serious expression Rigidity experienced by some people Late: Dimentia Early symptoms continue to manifest 1.5 million Americans 50,000 new patients/yr 27% attributed to genetic/heritability 73% attributed to Environmental factors 63 Average age of onset

  5. Causes Genetic Environment • SNCA (synuclein, alpha non A4 component of amyloid precursor): SNCA makes the protein alpha-synuclein. In brain cells of individuals with Parkinson's disease, this protein aggregates in clumps called Lewy bodies. • Mutations in the SNCA gene are found in early-onset Parkinson's disease. • PARK2 (Parkinson's disease autosomal recessive, juvenile 2): The PARK2 gene makes the protein parkin. Mutations of the PARK2 gene are mostly found in individuals with juvenile Parkinson's disease. Parkin normally helps cells break down and recycle proteins. • PARK7 (Parkinson's disease autosomal recessive, early onset 7): PARK7 mutations are found in early-onset Parkinson's disease. The PARK7 gene makes the DJ-1 protein, which may protect cells from oxidative stress. • PINK1 (PTEN-induced putative kinase 1): Mutations of this gene are found in early-onset Parkinson's disease. The exact function of the protein made by PINK1 is not known, but it may protect structures within the cell called mitochondria from stress. • LRRK2 (leucine-rich repeat kinase 2): LRRK2 makes the protein dardarin. Mutations in the LRRK2 gene have been linked to late-onset Parkinson's disease. • . • Living in Rural Area • Farming • Ranching • Fishing • Welding • Drinking well water • Exposure to Solvents • Pesticides • Insectacides • Fungacides

  6. Treatments for Disorder Carbidopa-levodopa (Parcopa). Levodopa Dopamine agonists MAO B inhibitors Catechol O-methyltransferase (COMT) inhibitors Anticholinergics Amantadine Deep brain stimulation N-Acetyl-Cystein (NAC) –slow the progression Parkinson's depletes an antioxidant in the brain called glutathione, so U of M researchers are now infusing a drug called N-Acetyl-Cystein (NAC) into the veins while patients are in the MRI machine. Then they monitor those antioxidant levels as more and more of the drug slowly flows into the brain. Minimal side effects, non-addictive. In addition, lifestyle is also geared at treating the symptoms. Aerobic exercise, balance PT and stretching are prescribed. Grow new neurons that release dopamine-using non embryonic or fetal sources. Current Drugs Brain implant Latest research Lifestyle Stem Cell

  7. Impact on Learning Impulse-control disorders: Compulsions-gambling, shopping, eating, sex, hobbies Punding-repetitive, purposeless Novelty seeking trait: Preference for new and different things, instead of familiar things. increase with dopamine boosting drugs where trait is less without medication. Memory: Short term problems

  8. Ethical Issues USA and Europe have different laws regarding ethics Xenografts-transplanted animal tissue into humans Stem cell sources Sham Surgery Controls in Research Paying research volunteers

  9. Current Controversies What is better: dopamine or dopamine agonists How much dopamine What is treatment of choice for newly diagnosed Patients driving

  10. Sources http://www.myfoxtwincities.com/story/19043257/slowing-the-progression-of-parkinsons-with-mri-and-nac-treatment http://www.youramazingbrain.org/brainchanges/parkinsonsnew.htm http://onlinelibrary.wiley.com/journal/10.1111/%28ISSN%291467-8519 Mary Holmay: U of MN Center for Orphan Drug Research, Maguire Translational Research Bldg. http://academic.sun.ac.za/stellmed/Articles/Internal_Medicine/AN11039.htm http://journals.lww.com/smajournalonline/Fulltext/2004/12000/Great_Shakes__Famous_People_With_Parkinson_Disease.13.aspx http://katekelsall.typepad.com/my_weblog/2008/08/the-controversy-surrounding-driving-with-parkinsons.html

More Related